Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification

Trial Profile

Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2016 Results assessing safety in comparison with historical controls (n=73) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 23 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2013 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top